Skip to main content

SABCS Highlights

SABCS Highlights

Health-Related Quality of Life in Patients with Metastatic Breast Cancer and Brain Metastases Treated with Tucatinib in Combination with Trastuzumab plus Capecitabine

SABCS Highlights

NALA Phase 3 Trial Outcomes in Patients Treated with Neratinib or Lapatinib

SABCS Highlights

HER2CLIMB-02: A Randomized, Double-Blind, Phase 3 Study of Tucatinib with T-DM1 for the Treatment of Unresectable Locally Advanced or Metastatic HER2-Positive Breast Cancer

SABCS Highlights

Final Overall Survival Analysis from the Randomized Phase 3 ExteNET Trial of Neratinib in Patients with HER2-Positive Early-Stage Breast Cancer

SABCS Highlights

Hormone Receptor Status Is Not a Factor in the HER2CLIMB Study of Tucatinib Combination Treatment for Patients with HER2-Positive Metastatic Breast Cancer

SABCS Highlights

Comparison of ARX788 and Lapatinib/Capecitabine in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer

SABCS Highlights

Efficacy, Safety, and Tolerability of Tucatinib in Combination with Letrozole and Palbociclib in Patients with HR-Positive, HER2-Positive Metastatic Breast Cancer

SABCS Highlights

Use of Circulating Tumor Cells to Guide Treatment with HER2 Therapy

SABCS Highlights

Real-World Analysis of Outcomes in Older Women with HER2-Positive Advanced Breast Cancer

SABCS Highlights

Effect of Brain Metastases in Real-World Treatment Patterns and Healthcare Resource Utilization Among HER2-Positive Metastatic Breast Cancer Patients

1
2

Page 1 of 2
Results 1 - 10 of 16